Voyager Therapeutics is trading at $1.90, down 5.94% on October 22, in line with broad market weakness. - The Nasdaq was down 2.19% and the S&P 500 down 1.37%. - Oil-supply concerns tied to Strait of Hormuz incidents and worries about AI spending are weighing on markets. - No confirmed company-specific catalyst was found; the October 21 CEO succession announcement is company news, but available reporting does not establish it as the reason for the decline.